Business Description
![Oncternal Therapeutics Inc Oncternal Therapeutics Inc logo](https://static.gurufocus.com/logos/0C00000B5Y.png?14)
Oncternal Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US40052B2079
Description
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 91.19 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 6.4 | |||||
3-Year EPS without NRI Growth Rate | 7.6 | |||||
3-Year FCF Growth Rate | 14.1 | |||||
3-Year Book Growth Rate | -39.6 | |||||
Future 3-5Y EPS without NRI Growth Rate | 22.6 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
9-Day RSI | 34.59 | |||||
14-Day RSI | 40.59 | |||||
6-1 Month Momentum % | 6.4 | |||||
12-1 Month Momentum % | -0.75 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.89 | |||||
Quick Ratio | 2.89 | |||||
Cash Ratio | 2.66 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.5 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -119.19 | |||||
ROA % | -97.91 | |||||
ROIC % | -1337.64 | |||||
ROC (Joel Greenblatt) % | -14160.9 | |||||
ROCE % | -122.03 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.82 | |||||
Price-to-Tangible-Book | 0.82 | |||||
EV-to-EBIT | 0.22 | |||||
EV-to-EBITDA | 0.22 | |||||
EV-to-Forward-Revenue | 0.5 | |||||
EV-to-FCF | 0.33 | |||||
Price-to-Net-Current-Asset-Value | 0.85 | |||||
Price-to-Net-Cash | 0.97 | |||||
Earnings Yield (Greenblatt) % | 454.55 | |||||
FCF Yield % | -194.82 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Oncternal Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -8.569 | ||
Beta | 0 | ||
Volatility % | 71.24 | ||
14-Day RSI | 40.59 | ||
14-Day ATR (€) | 0.000794 | ||
20-Day SMA (€) | 5.32 | ||
12-1 Month Momentum % | -0.75 | ||
52-Week Range (€) | 4.32 - 11.8 | ||
Shares Outstanding (Mil) | 2.96 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Oncternal Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Oncternal Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Oncternal Therapeutics Inc Frequently Asked Questions
What is Oncternal Therapeutics Inc(FRA:GTU)'s stock price today?
The current price of FRA:GTU is €5.32. The 52 week high of FRA:GTU is €11.80 and 52 week low is €4.32.
When is next earnings date of Oncternal Therapeutics Inc(FRA:GTU)?
The next earnings date of Oncternal Therapeutics Inc(FRA:GTU) is 2024-11-08 Est..
Does Oncternal Therapeutics Inc(FRA:GTU) pay dividends? If so, how much?
Oncternal Therapeutics Inc(FRA:GTU) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |